{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:54:33Z","timestamp":1788454473392,"version":"build-2803163510"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.biopha.2026.119012","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:36:15Z","timestamp":1768822575000},"page":"119012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hydrogen sulphide as a potential contributer to cardiovascular protection with sodium-glucose cotransporter 2 inhibition"],"prefix":"10.1016","volume":"195","author":[{"given":"Andrea","family":"Berenyiova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9922-4885","authenticated-orcid":false,"given":"Fedor","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119012_bib1","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2174\/138920111798280992","article-title":"The vasoactive role of nitric oxide: physiological and morphological aspects","volume":"12","author":"Cacanyiova","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119012_bib2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bph.13517","article-title":"Targeting vascular (endothelial) dysfunction","volume":"174","author":"Daiber","year":"2017","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000426","article-title":"Peripheral endothelial function and cardiovascular events in high-risk patients","volume":"2","author":"Matsuzawa","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2026.119012_bib4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.lfs.2003.07.032","article-title":"Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension","volume":"74","author":"Simko","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.607998","article-title":"Ivabradine and blood pressure reduction: underlying pleiotropic mechanisms and clinical implications","volume":"8","author":"Simko","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib6","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.2174\/13816128113196660749","article-title":"Pharmacological prevention of eNOS uncoupling","volume":"20","author":"Li","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2026.119012_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/biomedicines10051090","article-title":"Targeted strategy in lipid-lowering therapy","volume":"10","author":"Dayar","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119012_bib8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1161\/01.RES.84.12.1416","article-title":"Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene","volume":"84","author":"Freedman","year":"1999","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fphys.2017.01124","article-title":"Reduction of endothelial nitric oxide increases the adhesiveness of constitutive endothelial membrane ICAM-1 through Src-mediated phosphorylation","volume":"8","author":"Gao","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib10","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.3390\/molecules30132802","article-title":"The role of nitric oxide in cancer treatment: ally or foe?","volume":"30","author":"My\u015bliwiec","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119012_bib11","first-page":"1","article-title":"Heart failure and angiotensin converting enzyme inhibition: problems and perspectives","volume":"48","author":"Simko","year":"1999","journal-title":"Physiol. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1365-2362.2005.01507.x","article-title":"L-arginine fails to protect against myocardial remodelling in L-NAME-induced hypertension","volume":"35","author":"Simko","year":"2005","journal-title":"Eur. J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119012_bib13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/HYPERTENSIONAHA.107.100032","article-title":"LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling","volume":"50","author":"Paulis","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2026.119012_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2022.05.013","article-title":"Regulation of endothelial nitric oxide synthase in cardiac remodeling","volume":"364","author":"Musicante","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2026.119012_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FJC.0000000000001277","article-title":"Sodium ferulate inhibits rat cardiomyocyte hypertrophy induced by angiotensin II through enhancement of endothelial nitric oxide synthase\/nitric oxide\/cyclic guanosine monophosphate signaling pathway","volume":"80","author":"Luo","year":"2022","journal-title":"J. Cardiovasc. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib16","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1006\/jmcc.1997.0566","article-title":"Protein remodelling of the heart in NO deficient hypertension: the effect of captopril","volume":"29","author":"Pechanova","year":"1997","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2026.119012_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/jmcc.1999.1071","article-title":"Regression of chronic L -NAME-treatment-induced left ventricular hypertrophy: effect of captopril","volume":"32","author":"Bernatova","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2026.119012_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fmed.2020.00325","article-title":"Ivabradine ameliorates kidney fibrosis in L-NAME-induced hypertension","volume":"7","author":"Stanko","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118436","article-title":"PKR inhibitor imoxin prevents hypertension, endothelial dysfunction and cardiac and vascular remodelling in L-NAME-treated rats","volume":"262","author":"Kalra","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.niox.2017.04.009","article-title":"Dietary nitrite supplementation attenuates cardiac remodeling in l-NAME-induced hypertensive rats","volume":"67","author":"Sonoda","year":"2017","journal-title":"Nitric Oxide"},{"issue":"2","key":"10.1016\/j.biopha.2026.119012_bib21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33549\/physiolres.931391","article-title":"Is NO the king? Pathophysiological benefit with uncertain clinical impact","volume":"56","author":"Simko","year":"2007","journal-title":"Physiol. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib22","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1093\/emboj\/20.21.6008","article-title":"The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener","volume":"20","author":"Zhao","year":"2001","journal-title":"Embo J."},{"key":"10.1016\/j.biopha.2026.119012_bib23","article-title":"Changes in the vasoactive effects of nitric oxide, hydrogen sulfide and the structure of the rat thoracic aorta: the role of age and essential hypertension","volume":"69","author":"Berenyiova","year":"2018","journal-title":"J. Physiol. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1523\/JNEUROSCI.16-03-01066.1996","article-title":"The possible role of hydrogen sulfide as an endogenous neuromodulator","volume":"16","author":"Abe","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2026.119012_bib25","first-page":"1358","article-title":"Hydrogen sulfide ameliorates senescence in vascular endothelial cells through ameliorating inflammation and activating PPAR\u03b4\/SGLT2\/STAT3 signaling pathway","volume":"55","author":"Tian","year":"2023","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.biopha.2026.119012_bib26","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.3390\/ijms23169215","article-title":"Vasoactive effects of chronic treatment with fructose and slow-releasing H2S donor GYY- spontaneously hypertensive rats: the role of nitroso and sulfide signalization","volume":"23","author":"Berenyiova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jare.2020.02.013","article-title":"Hydrogen sulfide regulates insulin secretion and insulin resistance in diabetes mellitus, a new promising target for diabetes mellitus treatment? A review","volume":"27","author":"Zhang","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib28","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1073\/pnas.1202916109","article-title":"Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation","volume":"109","author":"Coletta","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib29","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.3390\/ijms22094749","article-title":"Fructose intake impairs the synergistic vasomotor manifestation of nitric oxide and hydrogen sulfide in rat aorta","volume":"22","author":"Berenyiova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib30","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib31","first-page":"736","article-title":"Significance of endothelial dysfunction amelioration for sodium-glucose cotransporter 2 inhibitor-induced improvements in heart failure and chronic kidney disease in diabetic patients","volume":"13","author":"Yanai","year":"2023"},{"key":"10.1016\/j.biopha.2026.119012_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119012_bib33","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/bph.16493","article-title":"Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction","volume":"181","author":"Doiron","year":"2024","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib34","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators, empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"73","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib35","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF trial committees and investigators, Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib36","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2026.119012_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1161\/CIRCULATIONAHA.109.920991","article-title":"Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice","volume":"122","author":"Calvert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119012_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/BSR20100003","article-title":"Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection","volume":"31","author":"Wang","year":"2011","journal-title":"Biosci. Rep."},{"issue":"200","key":"10.1016\/j.biopha.2026.119012_bib39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11325-019-01997-y","article-title":"Association between hydrogen sulfide and OSA-associated hypertension: a clinical study","volume":"24","author":"Shi","year":"2020","journal-title":"Sleep. Breath."},{"key":"10.1016\/j.biopha.2026.119012_bib40","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.3390\/ijms21124284","article-title":"Hydrogen sulfide treatment improves post-infarct remodeling and long-term cardiac function in CSE knockout and wild-type mice","volume":"21","author":"Ellmers","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib41","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.biopha.2026.119012_bib42","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/dom.15232","article-title":"Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials","volume":"25","author":"Heerspink","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2026.119012_bib43","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.3390\/ijms221910842","article-title":"Empagliflozin relaxes resistance mesenteric arteries by stimulating multiple smooth muscle cell voltage-gated K+ (KV) Channels","volume":"22","author":"Hasan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib44","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.3390\/molecules25122886","article-title":"Arterial hypertension and plasma glucose modulate the vasoactive effects of nitroso-sulfide coupled signaling in human intrarenal arteries","volume":"25","author":"Cacanyiova","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119012_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1479164117692766","article-title":"Chronic NaHS treatment decreases oxidative stress and improves endothelial function in diabetic mice","volume":"14","author":"Ng","year":"2017","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708177","article-title":"A SGLT2 inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro","volume":"12","author":"Xing","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/DMSO.S446904","article-title":"Sodium-glucose cotransporter protein 2 inhibitors: novel application for the treatment of obesity-associated hypertension","volume":"17","author":"Hu","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2026.119012_bib48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/cvr\/cvae257","article-title":"SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance","volume":"121","author":"Mroueh","year":"2025","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.12659\/MSM.908761","article-title":"Hydrogen sulfide attenuates hypertensive inflammation via regulating connexin expression in spontaneously hypertensive rats","volume":"24","author":"Ni","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.biopha.2026.119012_bib50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/antiox14050560","article-title":"Hydrogen sulfide (H2S) metabolism, iron overload, and apoptosis-autophagy equilibrium in vascular smooth muscle cells","volume":"14","author":"Arif","year":"2025","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2026.119012_bib51","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.3390\/ijms26073340","article-title":"The role of bacteria-derived hydrogen sulfide in multiple axes of disease","volume":"26","author":"Birg","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib52","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1126\/science.1162667","article-title":"H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase","volume":"322","author":"Yang","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119012_bib53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jb\/mvp111","article-title":"Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide","volume":"146","author":"Shibuya","year":"2009","journal-title":"J. Biochem"},{"key":"10.1016\/j.biopha.2026.119012_bib54","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fphar.2018.01066","article-title":"Hydrogen sulfide (H2S)-releasing compounds: therapeutic potential in cardiovascular diseases","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.33549\/physiolres.934905","article-title":"Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1\/RIP3\/MLKL-mediated necroptosis","volume":"71","author":"Ma","year":"2022","journal-title":"Physiol. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib56","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1139\/bcb-2023-0295","article-title":"Exogenous hydrogen sulfide prevents SOD2 degradation to safeguard renal function in diabetic kidney disease","volume":"102","author":"Yang","year":"2024","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119012_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/768607","article-title":"The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure","author":"Polhemus","year":"2014","journal-title":"Scientifica"},{"key":"10.1016\/j.biopha.2026.119012_bib58","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.112.000855","article-title":"H\u2082S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase","volume":"127","author":"Kondo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119012_bib59","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/jpet.111.184754","article-title":"Hydrogen sulfide regulates Na+\/H+ exchanger activity via stimulation of phosphoinositide 3-kinase\/Akt and protein kinase G pathways","volume":"339","author":"Hu","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119012_bib60","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/biomedicines11020612","article-title":"H2S prodrug, SG-1002, protects against myocardial oxidative damage and hypertrophy in vitro via induction of cystathionine \u03b2-synthase and antioxidant proteins","volume":"11","author":"Islam","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119012_bib61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000489606","article-title":"Low plasma hydrogen sulfide is associated with impaired renal function and cardiac dysfunction","volume":"47","author":"Kuang","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.biopha.2026.119012_bib62","first-page":"14","article-title":"Protective effects of hydrogen sulfide on chronic kidney disease by reducing oxidative stress, inflammation and apoptosis","volume":"17","author":"Askari","year":"2018","journal-title":"Excli. J."},{"key":"10.1016\/j.biopha.2026.119012_bib63","doi-asserted-by":"crossref","first-page":"11411","DOI":"10.1002\/jcp.27797","article-title":"The role of nitric oxide signaling in renoprotective effects of hydrogen sulfide against chronic kidney disease in rats: Involvement of oxidative stress, autophagy and apoptosis","volume":"234","author":"Shirazi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib64","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11033-024-09824-8","article-title":"Hydrogen sulfide upregulates hypoxia inducible factors and erythropoietin production in chronic kidney disease induced by 5\/6 nephrectomized rats","volume":"51","author":"Hajiaqaei","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2026.119012_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/s00467-025-07100-w","article-title":"Precision approaches to paediatric hypertension: linking pathophysiology to therapy","author":"Haseler","year":"2025","journal-title":"Pedia Nephrol."},{"key":"10.1016\/j.biopha.2026.119012_bib66","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41440-019-0318-3","article-title":"Melatonin as a rational alternative in the conservative treatment of resistant hypertension","volume":"42","author":"Simko","year":"2019","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib67","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.resp.2011.05.004","article-title":"Contributions of vascular inflammation in the brainstem for neurogenic hypertension","volume":"178","author":"Waki","year":"2011","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.biopha.2026.119012_bib68","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1365-2362.2012.02705.x","article-title":"Chronobiology of blood pressure: emerging implications of melatonin","volume":"42","author":"Simko","year":"2012","journal-title":"Eur. J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119012_bib69","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1093\/eurheartj\/ehz754","article-title":"Hygia project investigators. bedtime hypertension treatment improves cardiovascular risk reduction: the hygia chronotherapy trial","volume":"41","author":"Hermida","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2026.119012_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2003.11.081","article-title":"The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats","volume":"313","author":"Yan","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119012_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118831","article-title":"The antihypertension effect of hydrogen sulfide (H2S) is induced by activating VEGFR2 signaling pathway","volume":"267","author":"Zhu","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib72","first-page":"5","article-title":"Comparison of N-acetylcysteine and angiotensin converting enzyme inhibitors in blood pressure regulation in hypertensive patients","volume":"11","author":"Khaledifar","year":"2015","journal-title":"ARYA Atheroscler."},{"key":"10.1016\/j.biopha.2026.119012_bib73","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1177\/1535370217732325","article-title":"Hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease by the Akt\/eNOS\/NO pathway","volume":"242","author":"Jin","year":"2017","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib74","doi-asserted-by":"crossref","first-page":"H2093","DOI":"10.1152\/ajpheart.00088.2007","article-title":"Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats","volume":"293","author":"Shi","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yjmcc.2015.07.028","article-title":"GYY4137 attenuates remodeling, preserves cardiac function and modulates the natriuretic peptide response to ischemia","volume":"87","author":"Lilyanna","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2026.119012_bib76","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bjp.0706906","article-title":"Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide?","volume":"149","author":"Ali","year":"2006","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib77","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.bcp.2014.10.011","article-title":"Regulation of vascular tone in rabbit ophthalmic artery: cross talk of endogenous and exogenous gas mediators","volume":"92","author":"Salomone","year":"2014","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib78","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.lfs.2008.08.006","article-title":"Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition","volume":"83","author":"Kiss","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib79","first-page":"501","article-title":"The adaptive role of nitric oxide and hydrogen sulphide in vasoactive responses of thoracic aorta is triggered already in young spontaneously hypertensive rats","volume":"67","author":"Cacanyiova","year":"2016","journal-title":"J. Physiol. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib80","doi-asserted-by":"crossref","first-page":"H1446","DOI":"10.1152\/ajpheart.00506.2012","article-title":"Hydrogen sul\ufb01de dilates rat mesenteric arteries by activating endothelial large-conductance Ca2-activated K channels and smooth muscle Ca2 sparks","volume":"304","author":"Jackson-Weaver","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.115.227017","article-title":"Involvement of potassium channels and calcium-independent mechanisms in hydrogen sul\ufb01de-induced relaxation of rat mesenteric small arteries","volume":"356","author":"Hedegaard","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119012_bib82","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbrc.2007.05.063","article-title":"Hydrogen sulphide regulates intracellular pH in vascular smooth muscle cells","volume":"358","author":"Lee","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119012_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176266","article-title":"Hydrogen sulfide ameliorates hypertension and vascular dysfunction induced by insulin resistance in rats by reducing oxidative stress and activating eNOS","volume":"963","author":"Silva-Velasco","year":"2024","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib84","doi-asserted-by":"crossref","first-page":"663","DOI":"10.33549\/physiolres.932848","article-title":"Hydrogen sulfide improves the endothelial dysfunction in renovascular hypertensive rats","volume":"64","author":"Xue","year":"2015","journal-title":"Physiol. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib85","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.phrs.2016.06.029","article-title":"Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide","volume":"111","author":"Zhou","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib86","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40659-023-00466-x","article-title":"The effect of zofenopril on the cardiovascular system of spontaneously hypertensive rats treated with the ACE2 inhibitor MLN-4760","volume":"56","author":"Cacanyiova","year":"2023","journal-title":"Biol. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib87","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/biom12030457","article-title":"The vasoactive effect of perivascular adipose tissue and hydrogen sulfide in thoracic aortas of normotensive and spontaneously hypertensive rats","volume":"12","author":"Golas","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119012_bib88","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/biom11010108","article-title":"The vasoactive role of perivascular adipose tissue and the sulfide signaling pathway in a nonobese model of metabolic syndrome","volume":"11","author":"Cacanyiova","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119012_bib89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1054\/jcaf.2002.128001","article-title":"The impossible task of developing a new treatment for heart failure","volume":"8","author":"Packer","year":"2002","journal-title":"J. Card. Fail"},{"key":"10.1016\/j.biopha.2026.119012_bib90","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/17512433.2018.1447924","article-title":"What prevents cardioprotective drugs from reaching the market?","volume":"11","author":"Simko","year":"2018","journal-title":"Expert. Rev. Clin. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib91","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 inhibitors: the statins of the 21st century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2026.119012_bib92","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib93","article-title":"The evolution of sodium-glucose co-transporter-2 inhibitors in heart failure","volume":"13","author":"Fadiran","year":"2021","journal-title":"*Cureus"},{"key":"10.1016\/j.biopha.2026.119012_bib94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12471-021-01579-2","article-title":"The effects of antidiabetic agents on heart failure","volume":"30","author":"Wijnen","year":"2022","journal-title":"Neth. Heart J."},{"key":"10.1016\/j.biopha.2026.119012_bib95","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib96","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 investigators, dapagliflozin and cardiovascular outcomes in Type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib97","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-preserved trial investigators. empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib98","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12933-025-02767-9","article-title":"The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?","volume":"24","author":"Cinti","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119012_bib99","article-title":"A review of sodium-glucose cotransporter 2 inhibitor's clinical efficacy in heart failure with preserved ejection fraction","volume":"16","author":"Epperson","year":"2024","journal-title":"Cureus"},{"issue":"2019","key":"10.1016\/j.biopha.2026.119012_bib100","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib101","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","article-title":"Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance","volume":"141","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119012_bib102","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"DAPA-CKD trial committees and investigators, Effects of dapagliflozin in patients with kidney disease, with and without heart failure","volume":"9","author":"McMurray","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.biopha.2026.119012_bib103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119012_bib104","doi-asserted-by":"crossref","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, 2022. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 400, 2022, pp. 1788-1801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8.","DOI":"10.1016\/S0140-6736(22)02074-8"},{"issue":"1","key":"10.1016\/j.biopha.2026.119012_bib105","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjh.0000388487.43460.db","article-title":"Remodelling of the heart and vessels in experimental hypertension: advances in protection","volume":"28","author":"Simko","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2026.119012_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46016-z","article-title":"Effect of SGLT2 inhibition on salt-induced hypertension in female Dahl SS rats","volume":"13","author":"Kravtsova","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119012_bib107","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1074248418763808","article-title":"Beneficial effect of the SGLT2 inhibitor empagliflozin on glucose homeostasis and cardiovascular parameters in the cohen rosenthal diabetic hypertensive (CRDH) rat","volume":"23","author":"Younis","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119012_bib108","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1161\/HYPERTENSIONAHA.122.19177","article-title":"Dapagliflozin attenuates sympathetic and pressor responses to stress in young prehypertensive spontaneously hypertensive Rats","volume":"79","author":"Kim","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2026.119012_bib109","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press"},{"key":"10.1016\/j.biopha.2026.119012_bib110","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, Placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119012_bib111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119012_bib112","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","article-title":"Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.biopha.2026.119012_bib113","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.tcm.2022.05.005","article-title":"SGLT2 inhibitors in hypertension: role beyond diabetes and heart failure","volume":"33","author":"Gupta","year":"2023","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib114","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"n.d. Effect of Empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART. CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119012_bib115","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2026.119012_bib116","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib117","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s44161-023-00306-x","article-title":"Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?","volume":"2","author":"Packer","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib118","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/ejhf.2731","article-title":"How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure","volume":"24","author":"Packer","year":"2022","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2026.119012_bib119","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure. JACC Packer M. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2026.119012_bib120","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119012_bib121","doi-asserted-by":"crossref","first-page":"644","DOI":"10.5551\/jat.50807","article-title":"Empagliflozin's ameliorating effect on plasma triglycerides: association with endothelial function recovery in diabetic patients with coronary artery disease","volume":"27","author":"Sawada","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.biopha.2026.119012_bib122","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/jdi.13122","article-title":"Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: a pilot study","volume":"11","author":"Tochiya","year":"2020","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.biopha.2026.119012_bib123","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2026.119012_bib124","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11357-022-00563-x","article-title":"SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice","volume":"44","author":"Soares","year":"2022","journal-title":"Geroscience"},{"key":"10.1016\/j.biopha.2026.119012_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101527","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: role of heme oxygenase-1","volume":"32","author":"Behnammanesh","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2026.119012_bib126","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2337\/diabetes.55.02.06.db05-1103","article-title":"Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo","volume":"55","author":"Nieuwdorp","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2026.119012_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09503","article-title":"Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels","volume":"8","author":"Hasan","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2026.119012_bib128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jphs.2022.09.004","article-title":"Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure","volume":"150","author":"Hasan","year":"2022","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2026.119012_bib129","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.120.16466","article-title":"Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) inhibition-induced relaxation in arteries from human visceral adipose tissue","volume":"77","author":"De Stefano","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2026.119012_bib130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119012_bib131","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells","volume":"23","author":"Alsereidi","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119012_bib132","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/biom14050592","article-title":"Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway","volume":"14","author":"Han","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119012_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115213","article-title":"Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation","volume":"165","author":"Zhou","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway","volume":"52","author":"Cai","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2026.119012_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116505","article-title":"Canagliflozin inhibits PASMCs proliferation via regulating SGLT1\/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension","volume":"174","author":"Chen","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib137","doi-asserted-by":"crossref","DOI":"10.1080\/10641963.2023.2278205","article-title":"2023. Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation","volume":"45","author":"Tang","year":"2023","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.biopha.2026.119012_bib138","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12950-020-00264-2","article-title":"PPAR\u03b1 and PPAR\u03b2\/\u03b4 are negatively correlated with proinflammatory markers in leukocytes of an obese pediatric population","volume":"17","author":"Vargas-S\u00e1nchez","year":"2020","journal-title":"J. Inflamm. (Lond. )."},{"key":"10.1016\/j.biopha.2026.119012_bib139","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jare.2020.06.005","article-title":"Endogenous hydrogen sulfide improves vascular remodeling through PPAR\u03b4\/SOCS3 signaling","volume":"27","author":"Tian","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.752370","article-title":"Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"12","author":"Pabel","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib141","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"DELIVER trial committees and investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib142","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/ph18091259","article-title":"Empagliflozin protects against oxidative stress in the diabetic brain by inducing H2S formation","volume":"18","author":"Ozbek","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119012_bib143","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.freeradbiomed.2014.09.007","article-title":"Redox chemistry and chemical biology of H2S, hydropersulfides, and derived species: implications of their possible biological activity and utility","volume":"77","author":"Ono","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119012_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112750","article-title":"Hydrogen sulfide functions as a micro-modulator bound at the copper active site of Cu\/Zn-SOD to regulate the catalytic activity of the enzyme","volume":"42","author":"Wu","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2026.119012_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114694","article-title":"GYY4137, a H2S donor, ameliorates kidney injuries in diabetic mice by modifying renal ROS-associated enzymes","volume":"162","author":"Chen","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107095","article-title":"Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2","volume":"146","author":"Bruckert","year":"2022","journal-title":"Vasc. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib147","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005478","article-title":"The coordination of S-sulfhydration, S-nitrosylation, and phosphorylation of endothelial nitric oxide synthase by hydrogen sulfide","volume":"7","author":"Altaany","year":"2014","journal-title":"Sci. Signal"},{"key":"10.1016\/j.biopha.2026.119012_bib148","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2174\/138920111798281117","article-title":"Hydrogen sulfide regulates intracellular Ca2+ concentration in endothelial cells from excised rat aorta","volume":"12","author":"Moccia","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119012_bib149","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/21218","article-title":"Regulation of endothelium-derived nitric oxide production by the protein kinase Akt","volume":"399","author":"Fulton","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119012_bib150","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/7296874","article-title":"Exogenous hydrogen sulfide activates PI3K\/Akt\/eNOS pathway to improve replicative senescence in human umbilical vein endothelial cells","author":"Niu","year":"2023","journal-title":"Cardiol. Res. Pr."},{"key":"10.1016\/j.biopha.2026.119012_bib151","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2026.119012_bib152","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0008-6363(02)00809-X","article-title":"Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model","volume":"57","author":"Baartscheer","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"2007","key":"10.1016\/j.biopha.2026.119012_bib153","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00125-007-0628-x","article-title":"Enhanced activity of the myocardial Na+\/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt","volume":"50","author":"Darmellah","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2026.119012_bib154","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.WCB.0000088764.02615.B7","article-title":"Cerebrovascular vasodilation to extraluminal acidosis occurs via combined activation of ATP-sensitive and Ca2+-activated potassium channels","volume":"23","author":"Lindauer","year":"2003","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2026.119012_bib155","article-title":"Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.biopha.2026.119012_bib156","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCGENETICS.113.000404","article-title":"Mechanical unloading promotes myocardial energy recovery in human heart failure","volume":"7","author":"Gupte","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.biopha.2026.119012_bib157","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41569-025-01166-7","article-title":"Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets","volume":"22","author":"Mericskay","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2026.119012_bib158","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1096\/fj.04-2263com","article-title":"Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart","volume":"18","author":"Sharma","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2026.119012_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2026.119012_bib160","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41401-021-00805-2","article-title":"Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress","volume":"43","author":"Ren","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2026.119012_bib161","article-title":"An effective sodium-dependent glucose transporter 2 inhibition, canagliflozin, prevents development of hypertensive heart failure in dahl salt-sensitive rats","volume":"13","author":"He","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.664181","article-title":"Sodium-glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102521","article-title":"Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR\/HIF-1\u03b1 pathway","volume":"24","author":"Sun","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.biopha.2026.119012_bib164","doi-asserted-by":"crossref","first-page":"H1375","DOI":"10.1152\/ajpheart.00053.2015","article-title":"The role of sirtuins in cardiac disease","volume":"309","author":"Matsushima","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib165","article-title":"PGC-1\u03b1-mediated mitochondrial quality control: molecular mechanisms and implications for heart failure","volume":"10","author":"Chen","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119012_bib166","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fphar.2020.01150","article-title":"Exogenous hydrogen sulfide ameliorates diabetic myocardial fibrosis by inhibiting cell aging through SIRT6\/AMPK autophagy","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119012_bib167","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1002\/jcp.30214","article-title":"Hydrogen sulfide restores sevoflurane postconditioning mediated cardioprotection in diabetic rats: role of SIRT1\/Nrf2 signaling-modulated mitochondrial dysfunction and oxidative stress","volume":"236","author":"Zhang","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2026.119012_bib168","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.juro.2016.01.113","article-title":"Hydrogen sulfide induced erythropoietin synthesis is regulated by HIF proteins","volume":"196","author":"Leigh","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2026.119012_bib169","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2022.12.007","article-title":"Combining iron supplements with SGLT2 inhibitor-stimulated erythropoiesis in heart failure: should we be worried about thromboembolic events?","volume":"29","author":"Packer","year":"2023","journal-title":"J. Card. Fail"},{"key":"10.1016\/j.biopha.2026.119012_bib170","doi-asserted-by":"crossref","first-page":"30800","DOI":"10.1074\/jbc.M111.244780","article-title":"The acetylase\/deacetylase couple CREB-binding protein\/Sirtuin 1 controls hypoxia-inducible factor 2 signaling","volume":"287","author":"Chen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119012_bib171","first-page":"147","article-title":"Crosstalk between nitric oxide and hypoxia-inducible factor signaling pathways: an update","volume":"5","author":"Hendrickson","year":"2015","journal-title":"Res. Rep. Bioch"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:05:36Z","timestamp":1773983136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226000442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":171,"alternative-id":["S0753332226000442"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119012","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydrogen sulphide as a potential contributer to cardiovascular protection with sodium-glucose cotransporter 2 inhibition","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119012"}}